Anti-serum albumin binding variants
AssigneeGlaxo Group Limited
InventorsElena De Angelis, Carolyn Enever, Haiqun Liu, Oliver Schon
Life of this patent
Estimating the term…
Abstract
The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-14, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.
Claims27
An anti-serum albumin (SA) immunoglobulin single variable domain variant of DOM7h-14 (DOM7h-14 as shown in FIG. 1), wherein the variant comprises at least one mutation in CDR3 region 92 to 96 (position numbering according to Kabat) compared to DOM7h-14, and wherein the variant has from 1 to 8 changes compared to the amino acid sequence of DOM7h-14.
An anti-serum albumin (SA) immunoglobulin single variable domain variant of DOM7h-14, wherein the variant comprises a Ser at position 22 and a Glu at position 42 (numbering according to Kabat) compared to DOM7h-14, and wherein the variant has from 0 to 4 further changes compared to the amino acid sequence of DOM7h-14.
A nucleic acid comprising the nucleotide sequence of a DOM7h-14 variant selected from the nucleotide sequence of DOM7h-14-10 (SEQ ID NO:
- 1), DOM7h-14-18 (SEQ ID NO:
- 2), DOM7h-14-28 (SEQ ID NO:
- 4), DOM7h-14-36 (SEQ ID NO:
- 5) or DOM7h-14-19 (SEQ ID NO:
- 3) or a nucleotide sequence that is at least 80% identical to said selected sequence.
Dependencies are inferred from the claim text.